Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: A multicenter, retrospective study in Korea (KROG 11-04)

Breast Cancer Research and Treatment

Volumn 146, Issue 2, 2014, Pages 341-345

  Kim, Jin Hee ^a   Choi, Doo Ho ^b   Park, Won ^b   Ahn, Seung Do ^c   Kim, Su Ssan ^c   Ha, Sung Whan ^d   Kim, Kyubo ^d   Kim, Yong Bae ^e   Yea, Ji Woon ^f   Kang, Min Kyu ^f   Shin, Kyung Hwan ^g   Kim, Dong Won ^h   Lee, Ji Hae ⁱ   Suh, Chang Ok ^e  

^a Dongsan Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

ⁱ Ewha Womans University   (South Korea)

Author keywords

Boost; Breast cancer; Ductal carcinoma in situ; HER2; Radiation therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BOOST RADIOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; KOREA; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RADIATION RESPONSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT THERAPY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIAL; FEMALE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SOUTH KOREA; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84904110897     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3025-4     Document Type: Article

References (31)

1. Virnig BA, Tuttle TM, Shamliyan T et al (2010) Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102(3):170-178. doi:10.1093/jnci/djp482
2. Jung YS, Na KY, Kim KS et al (2011) Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program J. Breast Cancer 14(3):8
3. Riou O, Lemanski C, Guillaumon V et al (2012) Role of the radiotherapy boost on local control in ductal carcinoma in situ. Int J Surg Oncol 2012:748196. doi:10.1155/2012/748196
4. Schwartz GF, Solin LJ, Olivotto IA et al (2000) The consensus conference on the treatment of in situ ductal carcinoma of the breast, 22-25 April 1999. Breast 9(4):177-186
5. Holmberg L, Garmo H, Granstrand B et al (2008) Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 26(8):1247-1252. doi:10.1200/JCO.2007.12.7969
6. Wapnir I, Dignam J, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478-488. doi:10.1093/jnci/djr027
7. Cuzick J, Sestak I, Pinder S et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12(1):21-29. doi:10.1016/S1470-2045(10)70266-7
8. Bijker N, Meijnen P, Peterse J et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinomain situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):7
9. Bijker N, Peterse J, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263-2271 (Pubitemid 32366979)
10. Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41:162-177. doi:10.1093/jncimonographs/lgq039
11. Emdin S, Granstrand B, Ringberg A et al (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536-543. doi:10.1080/02841860600681569 (Pubitemid 44167203)
12. Poortmans PM, Collette L, Bartelink H et al (2008) The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. Cancer Radiother 12(6-7):565-570. doi:10.1016/j.canrad.2008.07.014
13. Omlin A, Amichetti M, Azria D et al (2006) Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the rare cancer network. Lancet Oncol 7(8):652-656. doi:10.1016/S1470-2045(06)70765- 3 (Pubitemid 44143777)
14. Wong P, Lambert C, Agnihotram R et al (2012) Ductal carcinoma in situ - the influence of the radiotherapy boost on local control. Int J Radiat Oncol Biol Phys 82(2):e153-e158. doi:10.1016/j.ijrobp.2011.03.045
15. Meattini I, Livi L, Franceschini D et al (2013) Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients. Eur J Surg Oncol 39(6):613-618. doi:10.1016/j.ejso.2013. 03.002
16. Yerushalmi R, Sulkes A, Mishaeli M et al (2006) Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary? Neoplasma 53(6):507-510 (Pubitemid 46133512)
17. Wai E, Lesperance M, Alexander C et al (2011) Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ. Cancer 117(1):54-62. doi:10.1002/cncr.25344
18. Tb Julian, Land SR, Wang Y (2008) Is boost therapy necessary in the treatment of DCIS? [Abstract]. J Clin Oncol 26(Suppl. 15):537
19. Monteau A, Sigal-Zafrani B, Kirova YM et al (2009) Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage. Int J Radiat Oncol Biol Phys 75(4):1021-1028. doi:10.1016/j.ijrobp.2008.12.014
20. Hathout L, Hijal T, Theberge V, Fortin B, Vulpe H, Hogue JC, Lambert C, Bahig H, Provencher L, Vavassis P, Yassa M (2013) Hypofractionated radiation therapy for breast ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 87(5):1058-1063. doi:10.1016/j.ijrobp.2013.08.026
21. Faverly DR, Burgers L, Bult P et al (1994) Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11(3):193-198 (Pubitemid 24308079)
22. Dunne C, Burke JP, Morrow M et al (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27(10):1615-1620. doi:10.1200/JCO.2008.17.5182
23. Lim YJ, Kim K, Chie EK, Han W, Noh DY, Ha SW (2014) Treatment outcome of ductal carcinoma in situ patients treated with postoperative radiation therapy. Radiat Oncol J 32(1):1-6. doi:10.3857/roj.2014.32.1.1
24. Holland P, Gandhi A, Knox W et al (1998) The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. Br J Cancer 77(1):110-114 (Pubitemid 28029781)
25. Wen X, Yang G, Mao W et al (2006) HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25(52):6986-6996 (Pubitemid 44684839)
26. Park K, Han S, Kim HJ et al (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48(6):702-707. doi:10.1111/j.1365-2559. 2006.02403.x
27. Noh J, Lee J, Choi D et al (2013) HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast 22(5):894-897. doi:10.1016/j.breast.2013.04.001
28. Piccart-Gebhart M, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1673-1684
29. Romond E, Perez E, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1685
30. Kuerer H, Buzdar A, Mittendorf E et al (2011) Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-48
31. Von Minckwitz G, Darb-Esfahani S, Loibl S et al (2012) Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer - results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 132(3):863-871